GLAX, LLC

Biotech · Private

SATB2 inhibitor small molecule for hepatocellular carcinoma treatment

Grants
$2.4M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
3 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Elimination Racial Disparities in Hepatocellular Carcinoma$399,997
Federal grantDepartment of Health and Human Services · Phase II · Elimination Racial Disparities in Hepatocellular Carcinoma$978,037
Federal grantDepartment of Health and Human Services · Phase II · Elimination Racial Disparities in Hepatocellular Carcinoma$1,001,965
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2408FLIK THERAPEUTICS, INC.——
2409AXENT BIOSCIENCES INC.——
2410CELLGRO TECHNOLOGIES, LLC——
2411GLAX, LLC——
2412AMPEDRNA BIOSCIENCES LLC——
2413SURVEY GENOMICS, INC.——
2414ATLAS BIOLOGICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 3 granted of 3

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.